 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...113114115116117118119120121122123...132133» |
- |||||| 5-fluorouracil / Generic mfg., everolimus / Generic mfg.
Enrollment open, Metastases: SEQTOR: Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrine Tumor (pNET) (clinicaltrials.gov) - Oct 31, 2014
P3, N=180, Recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Not yet recruiting --> Recruiting
- Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial initiation date, Combination therapy: Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Oct 30, 2014
P1, N=26, Not yet recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Initiation date: Sep 2014 --> Dec 2014
- | everolimus / Generic mfg.
Enrollment closed, Trial primary completion date: Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) (clinicaltrials.gov) - Oct 24, 2014
P2, N=50, Active, not recruiting, Sponsor: Mustafa Sahin
Initiation date: Sep 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Dec 2014
- | everolimus / Generic mfg.
Enrollment change: Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer (clinicaltrials.gov) - Oct 24, 2014
P2, N=45, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Dec 2014 N=30 --> 45
- | everolimus / Generic mfg.
New P2 trial: Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (clinicaltrials.gov) - Oct 24, 2014
P2, N=26, Not yet recruiting, Sponsor: Emory University
- Trial primary completion date: Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients (clinicaltrials.gov) - Oct 23, 2014
P4, N=60, Enrolling by invitation, Sponsor: University of California, San Francisco
N=30 --> 45 Trial primary completion date: Dec 2013 --> Mar 2015
- ||| everolimus / Generic mfg.
Phase classification, Trial initiation date, Trial primary completion date, Combination therapy: HEPHAISTOS: Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients (clinicaltrials.gov) - Oct 22, 2014
P4, N=330, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2013 --> Mar 2015 Phase classification: P3 --> P4 | Initiation date: May 2012 --> Jan 2012 | Trial primary completion date: Dec 2017 --> May 2017
- ||||| everolimus / Generic mfg.
New P2 trial, Metastases: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Oct 22, 2014
P2, N=70, Not yet recruiting, Sponsor: Emory University
- | Avastin (bevacizumab) / Roche
Enrollment closed: RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma (clinicaltrials.gov) - Oct 22, 2014
P1/2, N=45, Active, not recruiting, Sponsor: University of Utah
Phase classification: P3 --> P4 | Initiation date: May 2012 --> Jan 2012 | Trial primary completion date: Dec 2017 --> May 2017 Recruiting --> Active, not recruiting
- || Simulect (basiliximab) / Novartis
Clinical: TRANSFORMt: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (clinicaltrials.gov) - Oct 21, 2014
P4, N=2040, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Recruiting
- | everolimus / Generic mfg.
Trial completion: Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex (clinicaltrials.gov) - Oct 20, 2014
P1/2, N=28, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Recruiting Active, not recruiting --> Completed
- || telaglenastat (CB-839) / Calithera
Enrollment change, Combination therapy, Metastases: Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (clinicaltrials.gov) - Oct 17, 2014
P1, N=165, Recruiting, Sponsor: Calithera Biosciences, Inc
Active, not recruiting --> Completed N=100 --> 165
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial primary completion date, Metastases: Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=27, Active, not recruiting, Sponsor: University of Southern California
N=100 --> 165 N=42 --> 27 | Trial primary completion date: Apr 2015 --> Aug 2015
- ||| Sutent (sunitinib) / Pfizer
Real-world evidence, Real-world, Metastases: OPALINE : A Study Of Morbidity And Mortality At 2 Years (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=170, Not yet recruiting, Sponsor: Pfizer
- |||| everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: A091302: Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer (clinicaltrials.gov) - Oct 17, 2014
P2, N=56, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
N=42 --> 27 | Trial primary completion date: Apr 2015 --> Aug 2015 Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014 | Trial primary completion date: Jun 2016 --> Oct 2016
- |||| everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial primary completion date: Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients (clinicaltrials.gov) - Oct 15, 2014
P3, N=106, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014 | Trial primary completion date: Jun 2016 --> Oct 2016 Trial primary completion date: Dec 2018 --> Dec 2016
- |||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment open, Combination therapy, Metastases: CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) (clinicaltrials.gov) - Oct 15, 2014
P2, N=110, Recruiting, Sponsor: Cerulean Pharma Inc.
Trial primary completion date: Dec 2018 --> Dec 2016 Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Enrollment closed, Enrollment change, Monotherapy, Metastases: Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor (clinicaltrials.gov) - Oct 15, 2014
P1, N=16, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=20 --> 16
- everolimus / Generic mfg.
Trial primary completion date: RAD001 for Patients With Radioiodine Refractory Thyroid Cancer (clinicaltrials.gov) - Oct 11, 2014
P2, N=33, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=20 --> 16 Trial primary completion date: Jun 2014 --> Jun 2015
- everolimus / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Oct 11, 2014
P2, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Jan 2014 --> Jan 2015
- ||||| Xofigo (radium Ra-223 dichloride) / Bayer
New P2 trial, Combination therapy, Metastases: Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 11, 2014
P2, N=310, Not yet recruiting, Sponsor: Bayer
- Halaven (eribulin mesylate) / Eisai
Enrollment open, Trial initiation date, Metastases: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Oct 11, 2014
P1, N=45, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jan 2014 --> Jan 2015 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Oct 2014
- everolimus / Generic mfg.
Enrollment change, Metastases: Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy (clinicaltrials.gov) - Oct 10, 2014
P2, N=1, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Oct 2014 N=37 --> 1
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma (clinicaltrials.gov) - Oct 10, 2014
P2, N=18, Completed, Sponsor: SCRI Development Innovations, LLC
N=37 --> 1 Active, not recruiting --> Completed | N=41 --> 18 | Trial primary completion date: Dec 2014 --> Jul 2014
- Halaven (eribulin mesylate) / Eisai
Trial initiation date, Metastases: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Oct 4, 2014
P1, N=45, Not yet recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | N=41 --> 18 | Trial primary completion date: Dec 2014 --> Jul 2014 Initiation date: Oct 2014 --> Jan 2015
- ||||| New P4 trial: OCTandCAV: Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography (clinicaltrials.gov) - Oct 2, 2014
P4, N=278, Recruiting, Sponsor: University of Zurich
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
New P1 trial, Combination therapy: Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Oct 2, 2014
P1, N=26, Not yet recruiting, Sponsor: Mayo Clinic
- | Avastin (bevacizumab) / Roche
Enrollment open, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Sep 30, 2014
P2, N=25, Recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Initiation date: Oct 2014 --> Jan 2015 Active, not recruiting --> Recruiting
- ||||| Rituxan (rituximab) / Roche
Enrollment closed: PILLAR2: Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy (clinicaltrials.gov) - Sep 29, 2014
P3, N=740, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Sep 29, 2014
P2, N=112, Completed, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Absorb (everolimus-eluting bioresorbable vascular scaffold) / Abbott
Enrollment closed: Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=12, Active, not recruiting, Sponsor: Abbott Vascular
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || everolimus / Generic mfg.
Trial primary completion date: Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC (clinicaltrials.gov) - Sep 28, 2014
P2, N=64, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Mar 2015
- || everolimus / Generic mfg.
Trial primary completion date, Combination therapy: PROTECT: Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients (clinicaltrials.gov) - Sep 28, 2014
P4, N=234, Recruiting, Sponsor: Seoul St. Mary's Hospital
Trial primary completion date: Aug 2014 --> Mar 2015 Trial primary completion date: May 2014 --> Dec 2015
- everolimus / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date: RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder (clinicaltrials.gov) - Sep 28, 2014
P1/2, N=45, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: May 2014 --> Dec 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- ||||| Avastin (bevacizumab) / Roche
New P4 trial, Combination therapy, Metastases: IMPROVE: Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (clinicaltrials.gov) - Sep 28, 2014
P4, N=192, Recruiting, Sponsor: iOMEDICO AG
- temozolomide / Generic mfg., everolimus / Generic mfg.
New P2 trial, Metastases: Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) (clinicaltrials.gov) - Sep 28, 2014
P2, N=40, Recruiting, Sponsor: Haukeland University Hospital
- ||| Piqray (alpelisib) / Novartis
Enrollment open, Enrollment change, Metastases: Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors (clinicaltrials.gov) - Sep 28, 2014
P1, N=136, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting | N=100 --> 136
- |||||||||| 5-fluorouracil / Generic mfg., everolimus / Generic mfg.
New P3 trial, Metastases: SEQTOR: Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrine Tumor (pNET) (clinicaltrials.gov) - Sep 22, 2014
P3, N=180, Not yet recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
- everolimus / Generic mfg., bendamustine / Generic mfg.
Enrollment open: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Sep 22, 2014
P1, N=18, Recruiting, Sponsor: University of California, Davis
Not yet recruiting --> Recruiting | N=100 --> 136 Not yet recruiting --> Recruiting
- | everolimus / Generic mfg., bendamustine / Generic mfg.
New P1 trial: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Sep 16, 2014
P1, N=18, Not yet recruiting, Sponsor: University of California, Davis
- ||| Avastin (bevacizumab) / Roche
Enrollment closed: Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial (clinicaltrials.gov) - Sep 11, 2014
P2, N=240, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| everolimus / Generic mfg.
New P2 trial, Combination therapy: Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score (clinicaltrials.gov) - Sep 10, 2014
P2, N=66, Not yet recruiting, Sponsor: Yale University
- Trial initiation date, Trial primary completion date, Surgery, Metastases: Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus (clinicaltrials.gov) - Sep 9, 2014
P2, N=66, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting Initiation date: Feb 2014 --> Feb 2015 | Trial primary completion date: Feb 2016 --> Feb 2017
- | everolimus / Generic mfg.
Enrollment open: Everolimus for Cancer With TSC1 or TSC2 Mutation (clinicaltrials.gov) - Sep 9, 2014
P2, N=30, Recruiting, Sponsor: Dana-Farber Cancer Institute
Initiation date: Feb 2014 --> Feb 2015 | Trial primary completion date: Feb 2016 --> Feb 2017 Not yet recruiting --> Recruiting
- || Signifor (pasireotide) / Recordati
Trial primary completion date: Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer (clinicaltrials.gov) - Sep 8, 2014
P2, N=64, Recruiting, Sponsor: Thomas Jefferson University
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Jun 2015
- | everolimus / Generic mfg., erlotinib / Generic mfg., dasatinib / Generic mfg.
New P2 trial, IO biomarker: BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (clinicaltrials.gov) - Sep 8, 2014
P2, N=225, Not yet recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Fumena (vorolanib) / Tyrogenex, Betta Pharma
Enrollment open: VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Sep 8, 2014
P1/2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jun 2014 --> Jun 2015 Active, not recruiting --> Recruiting
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial completion, Trial primary completion date: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Sep 5, 2014
P2, N=38, Completed, Sponsor: Italian Sarcoma Group
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Mar 2014
- Absorb (everolimus-eluting bioresorbable vascular scaffold) / Abbott
Clinical: Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=12, Recruiting, Sponsor: Abbott Vascular
- ||||||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Trial primary completion date, Metastases: RADIANT-2: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (clinicaltrials.gov) - Sep 4, 2014
P3, N=429, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Mar 2014 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2010